Park Square has placed Greg Hoffman, Ph.D. as Vice President, Platform Biology at Deep Genomics. Deep Genomics is a pioneering biotechnology company that leverages artificial intelligence and genome biology to discover and develop life-saving RNA therapies.

Hoffman brings a wealth of experience developing novel platform technologies. He most recently oversaw the efforts to develop and enhance the discovery platforms at several innovative gene and cell therapy companies, including Arbor Biotechnologies, Obsidian Therapeutics, and Sana Biotechnology. Earlier in his career, Hoffman served as Senior Investigator at Novartis Institutes for BioMedical Research, where he joined after completing his training at Harvard Medical School. 

Hoffman received his B.A. in Biochemistry and his Ph.D. in Biophysics from Cornell University.